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Abstract: The development of therapeutic strategies to control the reactivation of the Herpes Simplex
Virus (HSV) is an unaddressed priority. In this study, we evaluated whether Tat, a HIV-1 protein
displaying adjuvant functions, could improve previously established HSV-specific memory responses
and prevent viral reactivation. To this aim, mice were infected with non-lethal doses of HSV-1
and, 44 days later, injected or not with Tat. Mice were then monitored to check their health status
and measure memory HSV-specific cellular and humoral responses. The appearance of symptoms
associated with HSV-reactivation was observed at significantly higher frequencies in the control
group than in the Tat-treated mice. In addition, the control animals experienced a time-dependent
decrease in HSV-specific Immunoglobulin G (IgG), while the Tat-treated mice maintained antibody
titers over time. IgG levels were directly correlated with the number of HSV-specific CD8+ T cells,
suggesting an effect of Tat on both arms of the adaptive immunity. Consistent with the maintenance
of HSV-specific immune memory, Tat-treated mice showed a better control of HSV-1 re-infection.
Although further studies are necessary to assess whether similar effects are observed in other models,
these results indicate that Tat exerts a therapeutic effect against latent HSV-1 infection and re-infection
by favoring the maintenance of adaptive immunity.
Keywords: biologically active HIV-1 Tat protein; HSV-1 infection; HSV-1 immune responses; persistence
of HSV-immune memory
1. Introduction
The development of preventive and therapeutic vaccines against Herpes Simplex Virus (HSV) is a
global health priority for many reasons: (1) genital herpes affects half a billion people between the ages
of 15 and 49 worldwide [1,2], causing diseases which are particularly severe and potentially lethal in
newborns and immunocompromised hosts; (2) HSV infection is one of the worldwide leading causes of
encephalitis, with high hospitalization and mortality rates when compared with other etiologic causes,
especially in immunosuppressed and elderly hosts [3,4]; (3) HSV-1 and 2 infections have also been
associated with the onset and morbidity of different non-communicable diseases, such as Alzheimer’s
disease [5] and atherosclerosis [6] and with an increased risk of horizontal and vertical HIV acquisition
and transmission [7,8] and bacterial vaginosis [9].
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Current HSV drugs are only efficacious against replicating HSV; they do not abrogate neuronal
latency nor do they eradicate the virus. Drug resistance has also been reported at high levels in
immunocompromised patients leading to severe outcomes, including encephalitis and death [10,11].
Thus, the only means to prevent HSV infection, virus spreading and reactivation from latency is the use
of vaccines against HSV, as also prioritized by WHO [12]. However, despite over 60 years of intensive
research, HSV vaccines—preventive or therapeutic —are not yet available [13].
Adaptive immunity is considered essential for long-lasting HSV control. CD8+ T cells found at
both mucosal sites [14] and trigeminal ganglia [15] and in particular those with an effector memory
(EM) phenotype, are directly responsible for the control of ocular and vaginal herpes [16–19] and
of reactivation from latency [20]. Humoral responses have been shown to contribute to protection,
although they are insufficient alone [16,21–23]. Therefore, strategies aimed at boosting HSV-specific
pre-existing immunity (memory lymphocytes) may be beneficial to prevent viral reactivation. Memory
lymphocytes are long-lived cells that, if necessary, will give rise to secondary responses, quicker
and more potent than primary ones. However, immune memory physiologically wanes due to
several causes, including aging [24–26] and pathological conditions such as transplantations [27],
immunodeficiency [28] and immunosuppressive infections [29]. In addition, the protection conferred
by memory recall responses is influenced by the heterogeneity of the memory pool [30,31]. However,
this heterogeneity is lost with physiological aging or after certain infections [32–35], resulting in the
accelerated loss of protection [24–26,36]. Therefore, the development of strategies aimed at improving
the maintenance and recall capacity of memory adaptive responses may be key for the long-term
control of HSV.
In previous studies aimed at developing a novel preventive vaccine against HSV, we generated a
HSV-based vector that expressed the HIV-1 Tat protein, a potent immune modulator [23,37,38] that can
increase and broaden protective humoral and cellular immunity against HSV thanks to its intrinsic
immunomodulatory properties that broaden and maintain CD8+ T cell responses against intracellular
pathogens while increasing anti-HSV1 antibody responses in mice [16,23]. We therefore wondered
if Tat could also improve previously established HSV-specific memory responses, thus preventing
viral reactivation.
2. Materials and Methods
2.1. Peptides and Antibodies
The biologically active HIV-1 Tat protein (HTLV-IIIB isolate, BH10 clone), provided by Diatheva,
was produced in Escherichia coli, as previously described [39], and formulated in saline buffer in the
presence of 1% saccarose and 1% human serum albumin and stored at −80 ◦C. The HSV-1 Kd-restricted
SSIEFARL (SSI) peptide, derived from glycoprotein B and corresponding to an immunodominant
CTL epitope, was used to evaluate T cell responses in C57BL/6 mice, as previously described [16].
Anti-Tat polyclonal (ANT0001) and monoclonal (NT3 2D1.1) antibodies were purchased, respectively,
from Diatheva (Diatheva, Fano, Italy) and the NIH Research and Reference Reagent Program
(German Town, MD, USA).
2.2. Herpes Simplex Virus Type 1 and Mice
Wild-type HSV type 1 (HSV-1, LV strain) was purified and titrated by the plaque assay method,
as previously described [23]. Seven to eight days before intravaginal (IV) inoculation or challenge, female
C57BL/6 mice (Charles-River, Lecco, Italy) were injected subcutaneously in the neck with 2 mg/100 µL of
Depo-Provera®(Depo-medroxy-progesterone acetate; Pharmacia & Upjohn). IV infection, with 103 or
104 plaque forming units (PFU) of HSV-1, and IV challenge, with 107 PFU of HSV1, were performed as
previously described [23]. The experiment with 103 PFU was performed with 10 animals. The experiment
with 104 PFU was performed twice with 32 and 12 animals, respectively. After HSV-1 infection and
challenge, mice were observed daily to monitor the appearance of local and/or systemic clinical signs of
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infection including death. Disease signs were classified as ruffled hair (score = 1), cold sores (score = 2),
limb paralysis (score = 3) and death (score = 4). Blood samples for detection of HSV1-specific immune
responses were collected from the retro-orbital plexus. At day 44 post-infection (p.i.), mice were mixed
and randomly assigned to receive Tat or buffer. Before day 44, the infection was asymptomatic or
mildly symptomatic (score = 1) in the majority of mice, and less than the 10% of the animals developed
vaginal lesions (cold sores). All animal experiments were conducted in conformity to European and
Institutional guidelines as ruled by the Italian Ministry of Health.
2.3. Determination of Cellular and Humoral Responses
Characterization of the number and phenotype of HSV-specific CD8+ T cells specific to the SSI
peptide was performed by flow cytometry using dextramers (Immudex, Copenhagen, Denmark),
as previously described [16]. The following antibodies were used: PerCP-Cy5.5 anti-CD3 (TONBO
Biosciences, Societa Italiana Chimici Rome, Italy); APC anti-CD62L (Immunotools, Friesoythe,
Germany); BV510 anti-CD44 (Biolegend, Campoverde S.r.l. Milano, Italy) and APC-H7 anti-CD8
(Becton Dickinson Milano, Italy). Samples were acquired on FACS Aria flow cytometer (BD) within 2 h
of fixation. Flow cytometry data were analyzed using FlowJo (version 9.5.3; Tree Star Inc., Ashland,
OR, USA).
Sera for antibody determinations were collected, stored and assessed by using the ELISA test for
the presence and titers of anti-HSV IgG, as previously described [23].
2.4. Statistics
Statistical analyses were performed using Prism software (GraphPad, San Diego, CA, USA).
Significance was assigned at p < 0.05. The Kaplan–Meier test was used to estimate the probability of
clinical manifestations. The magnitude of disease scores after challenge and of cellular responses were
analyzed using the two-tailed Mann–Whitney test after having assessed that data were not normally
distributed (Kolmogorov–Smirnov test). The kinetics of humoral responses were compared over time
in the same animals through a paired Student’s t test after having assessed that data were normally
distributed (Kolmogorov–Smirnov test).
3. Results and Discussion
3.1. The HIV-1 Tat Protein Has a Therapeutic Effect in Mice Infected with HSV-1
Our previous studies have indicated that the simultaneous administration of the Tat protein with
heterologous antigens improves both cellular and humoral immune responses against the antigens in
in vitro and murine models [23,38]. However, in in vitro experiments, this effect was not observed when
Tat was added to T cells after priming (i.e., during the expansion phase of the immune response) [40].
In agreement with these results, the administration of Tat to mice previously infected with HSV-1 7 days
before, did not improve immune responses nor protection against a lethal challenge (data not shown).
Since it has also been demonstrated in vitro that Tat exerts different effects on T cells depending on
their activation status [41], we wondered whether Tat may affect the pre-existing adaptive memory
immune responses. To test this hypothesis, C57BL/6 mice were infected intravaginally (IV) with a
low dose (104 PFU) of wild-type HSV-1. At day 44 p.i., 5 µg of the HIV-1 Tat protein—or, in the
control group, the equivalent volume of the buffer alone—was administered intradermally (ID) to
mice (Figure 1A). Animals were then monitored up to day 108 p.i. (day 64 after Tat administration).
Interestingly, we noticed a spontaneous appearance of signs such as vesicles and/or hair loss around
the genital area, starting a few days after treatment. These disease signs, compatible with a viral
reactivation, were significantly more frequent in controls than in Tat-treated mice (Figure 1B). Similar
results were found when Tat was administered to mice previously infected with a lower dose of HSV-1
(103 PFU) (Figure S1). Further, all Tat-treated mice developed significantly milder signs of infection
after an IV challenge with a high dose of HSV-1 (107 PFU) administered on day 108 post-infection.
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The difference in disease symptoms was particularly evident between 7 and 9 days after challenge
before the disease signs spontaneously healed in both groups (Figure 1C).
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Figure 1. Tat exerts therapeutic effects on previously acquired Herpes Simplex Virus (HSV-1) infection.
(A) Schematic representation of the experimental protocol and analysis. C57BL/6 mice were infected
by the intravaginal (IV) route with 104 plaque forming units (PFU)/mouse of HSV-1 and, on day 44
post-infection (p.i.), treated with HIV-1 Tat (5 µg) administered by the intradermal (ID) route into the
back. Controls were given only the Tat buffer. This treatment schedule was repeated in two independent
experiments with 16 and 6 mice per group, respectively. Disease scores were monitored up to day
108 p.i. in both experiments. The following treatments and analyses were performed in the second
experiment: On day 108 p.i. (i.e., day 64 after buffer ± Tat administration), mice were challenged IV
with 107 PFU/mouse of HSV-1 and observed for two weeks after challenge (day 121 p.i.). Mice were
bled on days 42 (before Tat treatment), 60 and 108 (before virus challenge) p.i. to analyze humoral and
T cell responses. (B) Analysis of disease signs after Tat treatment. Mice were observed twice a week
after Tat treatment to monitor the appearance of signs of disease. The Kaplan–Meier test was used to
estimate the percentage of mice developing clinical manifestation after treatment (n = 16 per group).
One representative experiment out of two is shown. (C) Analysis of signs of disease after HSV-1
challenge. Mice were observed every two days up to day 13 after challenge. For each group, mean
disease scores (± SEM) are shown and analyzed statistically using the two-tailed Mann–Whitney test
(n = 6 per group). * p < 0.05, ** p < 0.01.
Previous reports have shown that the transduction domain of Tat exhibits antiviral activities [42,43].
However, in our experiments we rule out a direct effect of Tat on HSV-1 virions, which might only
occur in the very remote case of an ongoing subclinical reactivation at the time of treatment (day 44).
Instead, we asked whether anti-Tat specific antibodies (Ab) could recognize and cross-react with HSV-1.
Although anti-Tat Ab are detectable in only a fraction of HIV-infected individuals [44,45], they are
effectively induced after administration of the Tat protein in humans [46–48] and animals [49–51].
Consistent with this, 100% of Tat-treated mice displayed anti-Tat IgG at both 60 and 108 days p.i.
(16 and 64 days after Tat inoculation, respectively), with mean titers in the range of 104 (data not
shown). To evaluate whether anti-Tat Ab hamper HSV-1 infectivity, an in vitro plaque reduction assay
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was performed by pre-incubating HSV-1 with sera of Tat- and/or HSV-1-immune mice. Anti-Tat Ab did
not prevent or reduce HSV-1 infection of Vero cells, in contrast to what was observed using anti-HSV-1
immune sera, regardless of the presence of anti-Tat IgG (Figure S2), thus excluding non-specific
effects of anti-Tat Ab on HSV-1 infectivity. Overall, these results indicate that the Tat protein exerts a
therapeutic effect against latent HSV-1 infection and re-infection.
3.2. Administration of the HIV-1 Tat Protein Prevents the Time-Dependent Reduction in Antigen-Specific
Adaptive Humoral Responses
We next assessed whether Tat may affect already established anti-HSV-1 immune responses.
To this aim, the amount of circulating CD8+ T cells specific to the HSV-1 Kd-restricted SSI epitope were
evaluated, since they play an important role in protection from HSV-1 infection [16,23]. Although
not statistically significant, increased numbers of SSI-specific CD8+ T cells were observed in the
blood of Tat-treated mice compared to that of control animals both at early (day 60 p.i.) and late
(day 108 p.i.) time points after administration of Tat (Figure 2A). Previously, we have reported that Tat
favors the late differentiation of T cells [38,40,52]. In addition, it has been shown that differentiated
(e.g., effector memory) T cells are important correlates of protection in HSV-1 infection [16–19,53]. Thus,
we characterized the phenotype of blood circulating SSI-specific CD8+ T cells. Consistent with the
mild signs of disease observed in mice previously infected with 104 PFU and then challenged with
107 PFU of HSV-1 (Figure 1C), all animals showed a high proportion (60–80%) of effector memory cells
(EM) within SSI-specific CD8+ T cells, regardless of their group (Figure 2B). In the very same mice,
the proportion of EM cells within the whole CD8 compartment (regardless of the antigen specificity)
was approximately 10–15% and directly correlated with the percentage of SSI-specific CD8+ T cells
(p < 0.0001) (Figure S3A), suggesting that HSV-specific CD8+ T cells affect and drive the size of the
EM subset. The frequency of EM SSI-specific CD8+ T cells, although slightly decreased over time,
persisted at levels of above 60% in both groups (Figure 2B). Therefore, the long-term cellular response
against HSV is mainly of EM type and Tat did not change this pattern. Considering the importance of
EM T cells for local responses, it will be important, in future experiments, to measure the amount and
phenotype of HSV-specific CD8+ T cells in mucosal tissues.
Surprisingly, while control mice experienced a physiological, time-dependent, decrease in
HSV-specific IgG, the same was not found in Tat-treated mice which, instead, showed similar levels
of HSV-specific IgG up to 108 days p.i. (Figure 2C). This indicates that Tat prevents the waning of
circulating antibodies against a heterologous antigen such as HSV-1. It will require further research to
determine whether this phenomenon is due to a direct effect of Tat on B cells or is T cell-dependent.
Very few studies, which are usually focused in the context of HIV-associated lymphomas [54–56],
have investigated the direct effects of Tat on B cells. Instead, it has been widely reported that Tat exhibits
potent immunomodulatory functions on antigen presenting cells [57,58], which may therefore be more
prone to presenting antigens and providing costimulation signals in HSV reactivation. In addition,
Tat can influence T-cell programming [38,40,52] and prevent apoptosis in T helper lymphocytes [59–62],
whose role in maintaining and recalling humoral responses has also been demonstrated [63–66]. In line
with the hypothesis of a strong interaction between cellular (CD8 and CD4) and humoral responses,
we observed a direct correlation between HSV-specific IgG levels and the percentage of circulating
SSI-specific CD8+ T cells (p = 0.009) (Figure S3B). Therefore, we may speculate that Tat effects on
the T-cell compartment also influence humoral immunity. This phenomenon is shared by several
pathogen-associated molecular patterns that, by modulating antigen presentation and costimulation to
helper T cells, affect both cytotoxic and humoral responses [67,68]. Indeed Tat, further to inducing
the release of IL-6 [69,70], which is important for B-cell maturation and T cell-dependent humoral
responses [71,72], binds the toll-like receptor (TLR4) [73]. TLR4 signaling profoundly influences the
functions of T and B lymphocytes [74–76] and may also rewire the metabolic programs of lymphocytes
towards lipid usage, thus potentially impacting the persistence and functionality of memory cells,
which are highly reliant on fatty acid oxidation [31,75]. We recently reported that Ab induced by a
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vaccine adjuvanted with a TLR4 ligand (TLR4L) lasted longer than those elicited by a similar vaccine
that did not contain a TLR4L [77]. Although in this work, we administered Tat to mice after the antigen
exposure and not simultaneously, we cannot rule out a general effect of TLR4L on plasma cell survival.
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Figure 2. Tat improves the maintenance of previously established immune memory responses.
(A) Analysis of SSIEFARL (SSI)-specific CD8+ T cells. Blood was collected from the retro-orbital
bleeding of mice (n = 5 per group) at days 60 and 108 p.i. (days 16 and 64 after buffer ± Tat inoculation,
respectively) to determine the percentage of SSI-specific CD8+ T cells. Dots represent the results of single
mice and lines represent median values. (B) Analysis of effector memory (EM) SSI-specific CD8+ T cells.
The percentage of peripheral blood circulating EM (CD44+ CD62L−) cells within the SSI-specific CD8+
T lymphocyte pool was measured at days 60 and 108 p.i. (days 16 and 64 after buffer ± Tat inoculation,
respectively). Bars represent the mean ± SEM (n = 5 per group). (C) Analysis of anti-HSV-1 antibody
responses. Sera were collected at days 42, 60 and 108 p.i. (two days before buffer ± Tat treatment,
and days 16 and 64 after buffer ± Tat inoculation, respectively) to assess the presence and titers of
HSV-specific IgG. Dots represent the mean ± SEM (n = 5 per group). A paired Student’s t test was used
to estimate the changes over time in HSV-specific IgG titers. n.s. = not significant.
The results obtained from human vaccine studies have already shown that HIV-infected subjects
vaccinated with Tat can improve memory adaptive responses to heterologous antigens [46]. The data
presented here confirm this observation and also suggest that this phenomenon is probably due not
only to the neutralization of the deleterious effects of Tat on HIV-infected subjects but also to the direct
support on the maintenance of adaptive immunity mediated by Tat. Together, these data indicate that
Tat can influence already established memory responses, preventing their physiological decline.
4. Conclusions
In this report, we have shown that the Tat protein of HIV exerts therapeutic effects in animals
with a previously acquired HSV-1 infection. Our observations suggest that these effects are mediated
by the maintenance of adaptive immunity, and in particular humoral responses, although the
molecular mechanism remains unknown. Recently, non-specific effects exerted by some vaccines
against heterologous antigens have been described, and this phenomenon was named “trained
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immunity” [78–80]. It is important to further investigate whether Tat displays similar mechanisms
and whether its effects may also be exerted on other antigens. In addition, further studies on innate
immune cells may help to identify the mechanism. However, these findings provide important clues
to the use of Tat for the control of latent HSV-1.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-393X/8/2/274/s1,
Figure S1: Tat exerts therapeutic effects on previously acquired HSV-1 infection, Figure S2: Anti-Tat antibodies do
not interfere with HSV-1 replication, Figure S3: Correlation between HSV-1-specific CD8+ T cells, effector memory
(EM) CD8+ T cells and HSV-1-specific humoral immunity.
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